Literature DB >> 26837769

Oncogenic Fusion Gene CD74-NRG1 Confers Cancer Stem Cell-like Properties in Lung Cancer through a IGF2 Autocrine/Paracrine Circuit.

Takahiko Murayama1, Takashi Nakaoku2, Masato Enari3, Tatsunori Nishimura4, Kana Tominaga5, Asuka Nakata4, Arinobu Tojo5, Sumio Sugano6, Takashi Kohno7, Noriko Gotoh8.   

Abstract

The CD74-Neuregulin1 (NRG1) fusion gene was recently identified as novel driver of invasive mucinous adenocarcinoma, a malignant form of lung cancer. However, the function of the CD74-NRG1 fusion gene in adenocarcinoma pathogenesis and the mechanisms by which it may impart protumorigenic characteristics to cancer stem cells (CSC) is still unclear. In this study, we found that the expression of the CD74-NRG1 fusion gene increased the population of lung cancer cells with CSC-like properties. CD74-NRG1 expression facilitated sphere formation not only of cancer cells, but also of nonmalignant lung epithelial cells. Using a limiting dilution assay in a xenograft model, we further show that the CD74-NRG1 fusion gene enhanced tumor initiation. Mechanistically, we found that CD74-NRG1 expression promoted the phosphorylation of ErbB2/3 and activated the PI3K/Akt/NF-κB signaling pathway. Furthermore, the expression of the secreted insulin-like growth factor 2 (IGF2) and phosphorylation of its receptor, IGF1R, were enhanced in an NF-κB-dependent manner in cells expressing CD74-NRG1. These findings suggest that CD74-NRG1-induced NF-κB activity promotes the IGF2 autocrine/paracrine circuit. Moreover, inhibition of ErbB2, PI3K, NF-κB, or IGF2 suppressed CD74-NRG1-induced tumor sphere formation. Therefore, our study provides a preclinical rationale for developing treatment approaches based on these identified pathways to suppress CSC properties that promote tumor progression and recurrence. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26837769     DOI: 10.1158/0008-5472.CAN-15-2135

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  The RARS-MAD1L1 Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma.

Authors:  Qian Zhong; Zhi-Hua Liu; Zhi-Rui Lin; Ze-Dong Hu; Li Yuan; Yan-Min Liu; Ai-Jun Zhou; Li-Hua Xu; Li-Juan Hu; Zi-Feng Wang; Xin-Yuan Guan; Jia-Jie Hao; Vivian W Y Lui; Ling Guo; Hai-Qiang Mai; Ming-Yuan Chen; Fei Han; Yun-Fei Xia; Jennifer R Grandis; Xing Zhang; Mu-Sheng Zeng
Journal:  Clin Cancer Res       Date:  2017-11-13       Impact factor: 12.531

2.  M5C-Related lncRNA Predicts Lung Adenocarcinoma and Tumor Microenvironment Remodeling: Computational Biology and Basic Science.

Authors:  Ming Bai; Chen Sun
Journal:  Front Cell Dev Biol       Date:  2022-05-03

3.  PDCD4 limits prooncogenic neuregulin-ErbB signaling.

Authors:  Juan Carlos Montero; Atanasio Pandiella
Journal:  Cell Mol Life Sci       Date:  2020-08-17       Impact factor: 9.261

4.  Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers.

Authors:  Alexander Drilon; Romel Somwar; Biju P Mangatt; Henrik Edgren; Patrice Desmeules; Anja Ruusulehto; Roger S Smith; Lukas Delasos; Morana Vojnic; Andrew J Plodkowski; Joshua Sabari; Kenneth Ng; Joseph Montecalvo; Jason Chang; Huichun Tai; William W Lockwood; Victor Martinez; Gregory J Riely; Charles M Rudin; Mark G Kris; Maria E Arcila; Christopher Matheny; Ryma Benayed; Natasha Rekhtman; Marc Ladanyi; Gopinath Ganji
Journal:  Cancer Discov       Date:  2018-04-02       Impact factor: 39.397

Review 5.  Insulin Receptor Isoforms in Physiology and Disease: An Updated View.

Authors:  Antonino Belfiore; Roberta Malaguarnera; Veronica Vella; Michael C Lawrence; Laura Sciacca; Francesco Frasca; Andrea Morrione; Riccardo Vigneri
Journal:  Endocr Rev       Date:  2017-10-01       Impact factor: 19.871

6.  Identification of potential diagnostic and prognostic biomarkers for LUAD based on TCGA and GEO databases.

Authors:  Qiangqiang Zheng; Shihui Min; Qinghua Zhou
Journal:  Biosci Rep       Date:  2021-06-25       Impact factor: 3.840

7.  Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers.

Authors:  Igor Odintsov; Marissa S Mattar; Allan J W Lui; Michael Offin; Christopher Kurzatkowski; Lukas Delasos; Inna Khodos; Marina Asher; Robert M Daly; Natasha Rekhtman; Elisa de Stanchina; Gopinath Ganji; Marc Ladanyi; Romel Somwar
Journal:  J Thorac Oncol       Date:  2021-04-08       Impact factor: 20.121

Review 8.  Drug resistance mechanisms of cancer stem-like cells and their therapeutic potential as drug targets.

Authors:  Takahiko Murayama; Noriko Gotoh
Journal:  Cancer Drug Resist       Date:  2019-09-19

9.  Landscape of cell heterogeneity and evolutionary trajectory in ulcerative colitis-associated colon cancer revealed by single-cell RNA sequencing.

Authors:  Quan Wang; Zhu Wang; Zhen Zhang; Wei Zhang; Mengmeng Zhang; Zhanlong Shen; Yingjiang Ye; Kewei Jiang; Shan Wang
Journal:  Chin J Cancer Res       Date:  2021-04-30       Impact factor: 5.087

Review 10.  NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.

Authors:  J Laskin; S V Liu; K Tolba; C Heining; R F Schlenk; P Cheema; J Cadranel; M R Jones; A Drilon; A Cseh; S Gyorffy; F Solca; M Duruisseaux
Journal:  Ann Oncol       Date:  2020-09-09       Impact factor: 51.769

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.